Markus Y Mapara
Columbia University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Markus Y Mapara as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:25 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07015684 · 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)Columbia University · recruiting · Sickling Disorder Due to Hemoglobin S · principal investigator
- Ph1/Ph2NCT06078696 · Siplizumab for Sickle Cell Disease TransplantColumbia University · terminated · Anemia, Sickle Cell · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Molecular Oncology Training ProgramT32CA203703 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2024 to 2026 · $550,829 awarded in 2026Same name and institution; not confirmed by an ID
- Short Term Training GrantT35HL007616 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2026 · $257,902 awarded in 2026Same name and institution; not confirmed by an ID
- Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple MyelomaR01CA252756 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2021 to 2025 · $478,447 awarded in 2025Same name and institution; not confirmed by an ID
- Graft Engineering of Allogeneic Hematopoietic Stem Cell Products with Molecular CascadesR01EB025221 · NIBIB · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2018 to 2021 · $646,892 awarded in 2021Same name and institution; not confirmed by an ID
- Role of STAT1 and STAT3 in Graft versus Host Disease and Graft versus Leukemia EfR01HL093716 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2008 to 2012 · $409,730 awarded in 2012Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:25 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.N Engl J Med · 20211,491 citationsRCR 82.9
- 376 citationsRCR 9.5
- Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.N Engl J Med · 2022362 citationsRCR 26.3
- 108 citationsRCR 3.0
- 102 citationsRCR 2.8
- Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization.Bone Marrow Transplant · 199941 citationsRCR 1.2
- 35 citationsRCR 1.5
- Standardized Semi-structured Psychosocial Evaluation before Hematopoietic Stem Cell Transplantation Predicts Patient Adherence to Post-Transplant Regimen.Biol Blood Marrow Transplant · 201929 citationsRCR 2.1
- Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.Leuk Lymphoma · 201528 citationsRCR 0.8
- Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.N Engl J Med · 202624 citationsRCR 12.0